

TRANSFER FACTOR PREPARATIONS AND ASSOCIATED METHODS

5

TECHNICAL FIELD

The present invention relates generally to preparations that include transfer factor and, more specifically, to edible preparations, such as drinks and solids that include transfer factor. Additionally, the present invention relates to methods for manufacturing edible, transfer factor-containing preparations and to methods that include administration of such preparations.

DISCLOSURE OF THE INVENTION

In one aspect, the present invention includes a drink that includes transfer factor. The drink includes an edible liquid or semisolid component and transfer factor. The liquid or semisolid component may comprise a fruit juice, a gelatin, a dairy-based product, or any other suitable, drinkable composition with components that are compatible with transfer factor. When mixed with the liquid component, the transfer factor may retain substantially all of one or more of its activities (*e.g.*, components of the liquid component may not interfere with one or more activities of transfer factor), or one or more of the activities of transfer factor may actually be enhanced by one or more components of the liquid component of the drink.

In another aspect, the present invention includes a composition with a fruit component and transfer factor. The fruit component may include at least one oligoproanthocyanidin (“OPC”)-containing fruit or an extract thereof. The term “extract” is broadly defined herein, including any OPC-including part of a fruit. Examples of extracts include, without limitation, juices (dilute, normal concentration, or concentrate), dehydrated fruit, and powders including one or more components of the fruit. Such a composition may be in a liquid form or a solid form, including but not limited to solid forms that are configured for at least partial dissolution or digestion in the mouth of a subject.

Another aspect of the present invention includes a process for making an edible preparation that includes transfer factor. The process includes mixing a fruit component with transfer factor. Preservatives may also be included in the mixture. The mixture may be chilled to prevent microbial growth. To further prevent microbial

growth, the mixture may be pasteurized before chilling. Alternatively, the mixture may be sterilized.

Other features and advantages of the present invention will become apparent to those of ordinary skill in the art through consideration of the ensuing description and
5 the appended claims.

BEST MODES FOR CARRYING OUT THE INVENTION

An exemplary embodiment of a drink that includes transfer factor may be liquid or semisolid. Such a drink may include an edible liquid or semisolid component, as
10 well as transfer factor. The liquid or semisolid component may, by way of nonlimiting example, comprise a fruit juice, a gelatin, a dairy-based product, or any other suitable, drinkable composition with components that are compatible with transfer factor. When mixed with the liquid component, the transfer factor may retain substantially all of one or more of its activities (*e.g.*, components of the liquid component may not interfere
15 with one or more activities of transfer factor), or one or more of the activities of transfer factor may actually be enhanced by one or more components of the liquid component of the drink. Such a drink may also include one or more preservatives. Alternatively, or in addition, lactoferrin may be included in a drink that includes transfer factor.

20 Another embodiment of an edible preparation that includes transfer factor also includes a fruit component. The edible preparation may also include one or more preservatives. Alternatively, or in addition, lactoferrin may be included in such an edible composition.

The fruit component includes at least one fruit that naturally includes OPC or a
25 juice or other extract of such a fruit. By way of nonlimiting example, the fruit component may include one or more of açai, elderberry, grape, and pomegranate or an extract thereof. OPC is a known antioxidant and may, therefore, be useful in neutralizing or otherwise acting against free radicals and other oxidants, which may adversely affect cell membranes, cause accelerated cellular aging, and are known or
30 believed to be at least indirectly responsible for a wide variety of disease states, as well as compromised immunity, in living beings.

The transfer factor component may include any type of transfer factor, as well as a combination of two or more types of transfer factor. For example, avian transfer

factor, bovine transfer factor, or any other type of transfer factor may be included in the transfer factor component. The transfer factor of the transfer component factor may be derived from any suitable, acceptable source. For example, avian transfer factor may be obtained from eggs, such as by a process disclosed in U.S. Patent 6,468,534 to Hennen et al. (hereinafter "Hennen"). An example of the manner in which bovine transfer factor may be obtained is disclosed in U.S. Patent 4,816,563 to Wilson et al. (hereinafter "Wilson"). Compositions that include two or more types of transfer factor, as well as processes for combining and processing two or more types of transfer factor, are disclosed in U.S. Patent 6,866,868 to Lisonbee et al. (hereinafter "Lisonbee").

10 Transfer factor is known or believed to improve the oxidative balance of a living being, as well as to enhance the effectiveness of antioxidants, as demonstrated by the disclosure of the international patent application filed pursuant to the Patent Cooperation Treaty and having International Publication Number WO 2004/041071 A2 (hereinafter "Dadali").

15 An edible preparation according to the present invention may also include one or more preservatives. Suitable preservatives, such as those accepted for use in foods and beverages, may be used. Examples of preservatives that may be included in an edible preparation of the present invention include, but are not limited to, sodium benzoate and preservatives from the paraben family of chemicals.

20 Lysozyme, when used in an edible preparation that incorporates teachings of the present invention, acts as a preservative. While lysozyme has been used as a preservative in cheeses, it is not believed to have been previously used in this capacity in edible preparations that include fruits or extracts thereof.

 Lactoperoxidase may also, or alternatively, be included in edible preparations that incorporate teachings of the present invention. Lactoperoxidase is another preservative that has been used in dairy products, but it is believed that lactoperoxidase has not been used to preserve edible compositions that include fruits or extracts of fruits.

 Lactoferrin is known or believed to stimulate the immune system and may work in concert with transfer factor to improve the immunity of a subject that receives an edible preparation that incorporates teachings of the present invention. Lactoferrin is also known to starve bacteria and, thus, may act as a preservative when included in an edible preparation that incorporates teachings of the present invention.

In an exemplary embodiment, the edible preparation may be a liquid, a semisolid, or a solid. A liquid form of edible preparation may be in the form of a fruit juice. A solid form of edible preparation may be configured for consumption as a solid (e.g., as a chewable tablet, an effervescent tablet, a dissolvable wafer, a dissolvable gel strip, etc.), for reconstitution as a liquid, or in any other suitable fashion.

A liquid edible preparation that incorporates teachings of the present invention is described in the following example:

EXAMPLE 1

An example of a formulation for a liquid edible preparation that includes transfer factor follows:

TABLE 1

Ingredient	% of Total (w/v)	Density (g/ml)	% of Total Juices (v/v)
Water	76.681	1.000	
Apple Juice	5.146	1.346	19
Purple Grape Juice	5.100	1.330	19
Glycerine	3.980	1.249	
Blueberry Juice	3.772	1.315	18
Transfer Factor E-XF	1.912		
Pomegranate Juice	1.480	1.315	15
Grape color concentrate (e.g., MEGANATURAL™ purple from Canandaigua Concentrates & Colors, a Division of Canandaigua Wine Company of Madera, California)	0.500	1.306	
Vitamin C	0.498		
Elderberry Juice	0.419	1.315	15
Flavorings			
Berry flavor (BE-01407)	0.198	1.000	
Berry flavor (BE-01271)	0.055	1.000	
Natural Vanilla (VA-01239)	0.165	1.000	
Açaí Powder	0.318		14
Lactoferrin	0.191		
Lysozyme	0.014		
Lactoperoxidase	0.003		

Transfer Factor E-XF includes bovine transfer factor from cow colostrum and avian transfer factor from the yolk of a chicken's egg.

The flavorings listed in TABLE 1 are available from Flavors Inc.

A daily dosage of about one fluid ounce (about 30 ml) or more of a composition with ingredients in the proportions listed in TABLE 1 may be administered to or consumed by a subject. In addition to the numerous known and believed benefits of antioxidants, including the benefits of OPC and OPC-containing fruits such as açai,
5 administration or consumption of an edible composition that incorporates teachings of the present invention provides the subject with the additional and sometimes synergistic beneficial affects of transfer factor, which are known in the art, as evidenced by the disclosures of Dadali, Hennen, Lisonbee, and Wilson.

10 An edible preparation may be made by mixing components of a food base with transfer factor by processes that are known in the art. Additionally, lactoferrin or preservatives, including, without limitation, lysozyme, lactoperoxidase, and other food preservatives, may be mixed with the food base.

Of course, the types of processes that are used and, possibly, the order in which
15 certain ingredients are included, may depend in part upon the form, or state (*e.g.*, liquid, solid, semisolid, etc.), of the various ingredients that are mixed with one another, their solubilities, and the desired form, or state, of the resulting edible preparation (*i.e.*, whether the edible preparation is liquid, semisolid, solid, includes carbonation, etc.). Suitable processes that may be used to manufacture edible preparations of a variety of
20 different forms are well known and within the skill of those in the relevant art.

A liquid edible preparation may be manufactured with liquid ingredients or liquid and dissolvable solid (*e.g.*, powder, crystalline, etc.) or semisolid (*e.g.*, gel, paste, etc.) ingredients. Alternatively, dry ingredients may be mixed with one another, then reconstituted (*e.g.*, in water, juice, etc.) by either the manufacturer, a distributor, or an
25 end-user to liquid form.

Known techniques, such as those disclosed in "Principles and Practices of Small- and Medium-Scale Fruit Juice Processing," Food and Agricultural Organization of the United Nations (FAO) Services Bulletin 146 (Rome, 2001), may be used in one or more parts of a process for manufacturing fluid edible preparations that incorporate
30 teachings of the present invention.

A solid or semisolid edible preparation may be manufactured with dry, semisolid, or liquid components, or combinations thereof, then, if desired, dried (*e.g.*, by dehydration processes, etc.) to a desired state. A solid edible preparation may be

manufactured in any suitable form (*e.g.*, chewable tablet, dissolvable wafer or gel, chewing gum, reconstitutable powder, etc.) by processes that are well known in the art. Of course, various additional ingredients (*e.g.*, fillers, sweeteners, wicking agents, etc.) may be used to facilitate manufacture of the edible preparation in a desired solid form.

5 Examples of additional ingredients that may be included in a solid or semisolid edible preparation include, but are not limited to, one or more of the following: pullulan, corn starch, gelatin, dextrin, glycerin, carrageenan, xanthan gum, dextrose, corn syrup, and bees wax. The incorporation of additional ingredients into an edible composition is well within the skill of one who practices in the art.

10 Without limiting the scope of the present invention, various types of solid edible compositions may be formed by known processes, including, but not limited to, the processes that are disclosed at “Tablets,” <http://pharmlabs.unc.edu/tablets/text.htm> and in U.S. Patents 6,326,028 to Nivaggioli et al., 6,733,781 to Abu-Izza et al., and 6,811,795 to Wehling.

15 Processes that are used to manufacture edible preparations that are in a form that is not completely dry, such as a liquid or semisolid state, may be effected at a low temperature (*e.g.*, between about 0° C. and about 10° C., at about 4° C, etc.), such as in a refrigerated environment, then transported and stored at such temperatures to reduce the likelihood of microbial growth or proliferation therein.

20 Alternatively, an edible preparation that is in a form that is not completely dry may be pasteurized or sterilized. Pasteurization processes, which decrease the number of microorganisms present, but do not entirely eliminate the microorganisms, improve the stability of products that are to be stored at reduced temperatures (*e.g.*, frozen or refrigerated, or “chilled”). When an edible preparation is sterilized, all or substantially
25 all microorganisms therein are killed or inactivated, facilitating prolonged storage of the edible preparation at room temperature or even higher temperatures.

As an example, an edible preparation that includes transfer factor may be sterilized by known superheated steam injection processes. The temperatures and durations of such processes depend, of course, upon the form and ingredients of the
30 composition to be sterilized. When making a liquid preparation, the resulting edible preparation may be “flash” heated to a particular temperature (*e.g.*, 120° C.) for a corresponding duration (*e.g.*, two seconds). Alternatively, a sterilization or pasteurization process of different duration and temperature may be used, so long as the

duration and temperature of the process are in substantial accord with a practice that has been accepted in the art, such as use of the following equation:

$$t_p = 5 \cdot 10^{14} \cdot e^{-0.4353 \cdot T_{mo}},$$

where t_p is the minimum duration of the process, and T_{mo} is the temperature at which the process is effected.

Of course, processes that reduce microbial load on an edible preparation of the present invention need not comprise heat-treatment techniques. Sterilization or other microbial load-reducing techniques that employ other means (*e.g.*, filtration, antimicrobial ingredients, etc.) may also be used in manufacturing an edible preparation. Examples of suitable processes are disclosed in Hughes, D. E., and Nyborg, W., "Minimally Processed Fruits and Vegetables: Reducing Microbial Load by Nonthermal Physical Treatments," Food Technology 52(6): 66-71 (1997).

It is desirable that, following pasteurization or sterilization, the transfer factor retain some if not substantially all or all of its activity. A variety of pasteurization or sterilization processes may be employed, including pasteurization or sterilization processes that may be used to reduce microbial counts or completely eliminate microorganisms from foods. As many sterilization processes are known to significantly reduce the activity of certain proteins, including antibodies, a study was performed to determine whether transfer factor retains at least some of its activity following sterilization.

In the study, mouse footpad assay techniques, similar to those disclosed in J. Natl. Cancer Inst. 55(5):1089-95 (Nov. 1975), were used to determine the affects of heat pasteurization or sterilization processes (specifically, superheated steam injection processes) on edible preparations including transfer factor. Two sterilized samples were compared with an unsterilized sample, as well as with a negative control and a positive control.

Separate populations of six mice were tested for each of the five samples and controls. The tests were conducted in two phases, a first that immediately followed heat sterilization of the samples, and a second that was conducted after storing the two heat sterilized samples at a temperature of about 40° C. for about three months, which is well-accepted in the art to be the equivalent of about one year of storage at room temperature. Thirty different mice were used in each phase of the study. The following procedures were followed in each phase of the study

In the positive control (*i.e.*, the “fifth group”), fourteen days prior to testing, six BALB/c mice having ages of about nine weeks to about ten weeks were anesthetized with isoflurane. Then 0.02 ml of an about 50/50 (wt/wt) mixture of Freund’s adjuvant and bovine rhinotracheitis virus diarrhea vaccine was administered intramuscularly to each mouse by way of two injections at the base of each side of the mouse’s tail. This early injection of antigen allows the mice of the positive control group to elicit their own primary immune response and secondary, or delayed-type hypersensitivity response to the antigen. The mice of the other five groups were not preexposed to the antigen in this manner.

10 About twenty-four hours before evaluating the hind footpads of the mice, the six BALB/c mice of each group, which were of similar age to the mice of the positive control group, were anesthetized with isoflurane. About 0.5 ml of a sample solution or control solution was then administered by subcutaneous injection at the back of the neck of each mouse.

15 In the first group (*see* EXAMPLE 2 below), which was the negative control group, the back of the neck of each mouse was injected with about 0.5 ml of sterile saline solution.

 In the second group (*see* EXAMPLE 3 below), the sample solution included 16% solids (w/v) of a reconstituted (in distilled, deionized water) lyophilized colostrum fraction that included transfer factor. The solution was set at a pH of 4.0, which was intended to estimate the pH of a fruit juice preparation (the actual pH of which is about 3.6 or about 3.7). Following reconstitution and pH adjustment, the solution was sterilized by heating the same to a temperature of about 120° C. for about two seconds.

25 In the third group (*see* EXAMPLE 4 below), the sample solution included 16% solids (w/v) of a reconstituted (in distilled, deionized water) lyophilized colostrum fraction that included transfer factor. The pH of the resulting solution was not adjusted and, thus, was neutral (*i.e.*, 7.0) or slightly basic (*i.e.*, greater than 7.0)). Following reconstitution, the solution was sterilized by heating the same to a temperature of about 120° C. for about two seconds.

 In the fourth group (*see* EXAMPLE 5 below), the sample solution was a concentrate of a colostrum fraction that included transfer factor, which had been diluted

to about 16% solids (w/v) in distilled, deionized water. This solution was not heat sterilized or pH adjusted.

The mice of the fifth group (*see* EXAMPLE 6 below), which was the positive control group, received sterile saline solution.

5 At the start of the mouse footpad assay, the right hind footpad and the left hind footpad of each mouse were measured, such as with a Starrett gauge. The right hind footpad of each of the thirty mice during each phase of the study was then subcutaneously injected with an antigen-containing solution. The footpad on the left hind foot of each of the thirty mice in each phase, which was used as a control, was
10 injected with about the same volume of a control solution, such as a sterile saline diluent, as the volume of antigen-containing solution that was injected into right hind footpad.

 After a sufficient amount of time (*e.g.*, about twenty-four hours) for the secondary immune response components of the immune system of each mouse to
15 respond, each mouse was again anesthetized and the distances across right and left hind footpads were again measured. A significant amount of swelling, determined by an increase in the distance across a right hind footpad of a mouse from the initial measurement to the second measurement, is indicative of the occurrence of a delayed-type hypersensitivity reaction in that footpad.

20 The results of the mouse foot pad assays, and some accompanying analysis, are set forth in EXAMPLES 2 through 5 and 7:

EXAMPLE 2

 In the first phase of the study, the footpads on the right hind feet of the six mice
25 of the negative control, or first group, exhibited, on average, about 6.35 micrometers more swelling about twenty-four hours after they were injected with the antigen solution than the swelling measured in the footpads of the left hind feet of these mice, which were merely inoculated with sterile saline.

 The results for the negative control group during the second phase of the study
30 are set forth in the following table:

TABLE 2

Mouse	Foot (left/right)	Foot Pad (untreated) (micrometers)	Foot Pad (final) (micrometers)	Foot Pad (difference) (micrometers)
1	Left (control)	1930.40	1955.80	25.40
	Right (test)	1905.00	1930.40	25.40
2	Left (control)	1981.20	2006.60	25.40
	Right (test)	2006.60	2057.40	50.80
3	Left (control)	2057.40	2057.40	0.00
	Right (test)	2032.00	2057.40	25.40
4	Left (control)	2006.60	2032.00	25.40
	Right (test)	2032.00	2057.40	25.40
5	Left (control)	1955.80	2006.60	50.80
	Right (test)	1930.40	1955.80	25.40
6	Left (control)	1905.00	1930.40	25.40
	Right (test)	1876.60	1955.80	76.20

Similar to the results from the first phase, the footpads of the right hind feet of the mice of the negative control group exhibited, on average, only 12.70 micrometers more swelling about twenty-four hours after antigen injection than the footpads of the left hind feet of the same mice exhibited twenty-four hours after sterile saline injection. As twenty-four hours is not a sufficient period of time for a mouse to mount a primary (*i.e.*, antibody-mediated) immune response to the antigen, these insignificant differences in swelling show that the mice did not exhibit a significant secondary immune response to the antigen.

EXAMPLE 3

In the first phase of the study, about twenty-four hours after they were injected with the antigen solution, the footpads on the right hind feet of the six mice of the second group of mice (which mice had previously been inoculated with a solution including 16% solids (w/v) colostrum at pH=4.0) swelled, on average, by 50.80 micrometers more than the swelling that was measured in the footpads of the left hind feet of these mice. These results indicate that there was a greater secondary, or delayed-type hypersensitivity, immune response in the footpads into which antigen was injected than in the footpads into which no antigen was injected, which were likely swollen merely because they were pierced by a needle.

In the second phase of the study, similar results were obtained, as set forth in the following table:

TABLE 3

Mouse	Foot (left/right)	Foot Pad (untreated) (micrometers)	Foot Pad (final) (micrometers)	Foot Pad (difference) (micrometers)
1	Left (control)	1955.80	2006.60	50.80
	Right (test)	1981.20	2057.40	76.20
2	Left (control)	1930.40	2006.60	76.20
	Right (test)	1955.80	2108.20	152.40
3	Left (control)	1955.80	2006.60	50.80
	Right (test)	1981.20	2082.80	101.60
4	Left (control)	2032.00	2057.40	25.40
	Right (test)	2057.40	2108.20	50.80
5	Left (control)	1930.40	2006.60	76.20
	Right (test)	1955.80	2032.00	76.20
6	Left (control)	2057.40	2108.20	50.80
	Right (test)	2032.00	2159.00	127.00

5 More specifically, the footpads of the right hind feet of the six mice of the second group swelled so that they measured, on average, 42.33 micrometers more than the swelling that was measured in the footpads of the left hind feet of these mice before and after inoculation of their foot pads with the antigen solution. The similar results between the first and second phases of the study indicate that once a liquid solution that includes transfer factor has been heat sterilized there is little or no change in the activity of the transfer factor after prolonged storage of the solution.

EXAMPLE 4

15 The results for the third group of mice (which mice had previously been inoculated with a solution including 16% solids (w/v) colostrum at normal pH) were similar to the results for the second group in the first and second phases of the study.

In the first phase of the study, about twenty-four hours after the footpad injections, the antigen solution-inoculated footpads on the right hind feet of the six mice of the third group of mice swelled, on average, by 35.98 micrometers more than the swelling that was measured in the sterile saline-inoculated footpads of the left hind feet of these mice. These results indicate that there was a greater secondary, or delayed-type hypersensitivity, immune response in the footpads into which antigen was

injected than in the footpads into which no antigen was injected, which were likely swollen merely because they were pierced by a needle.

In the second phase of the study, similar results were obtained, as set forth in the following table:

5

TABLE 4

Mouse	Foot (left/right)	Foot Pad (untreated) (micrometers)	Foot Pad (final) (micrometers)	Foot Pad (difference) (micrometers)
1	Left (control)	2006.60	2032.00	25.40
	Right (test)	2032.00	2082.80	50.80
2	Left (control)	2057.40	2057.40	0.00
	Right (test)	2006.60	2108.20	101.60
3	Left (control)	1981.20	2006.60	25.40
	Right (test)	2057.40	2082.80	25.40
4	Left (control)	2006.60	2057.40	50.80
	Right (test)	2032.00	2082.80	50.80
5	Left (control)	2057.40	2082.80	25.40
	Right (test)	2082.80	2159.00	76.20
6	Left (control)	2082.80	2108.20	25.40
	Right (test)	2108.20	2159.00	50.80

These results show that the footpads of the right hind feet of the six mice of the third group swelled so that they measured, on average, 33.87 micrometers more than the swelling that was measured in the footpads of the left hind feet of these mice before and after inoculation of the foot pads with the antigen solution. The similar results between the first and second phases of the study indicate that, following prolonged storage, there was little or no change in the activity of the transfer factor in a heat-sterilized solution.

10

EXAMPLE 5

15

These results were confirmed by the results that were obtained from the fourth group of mice. In particular, during the first phase of the study, the footpads of the right hind feet of mice in the fourth group (which included mice that had been inoculated with a diluted liquid colostrum fraction that was not heat sterilized) exhibited, on average, about 35.98 micrometers more swelling than the foot pads of left hind feet of these mice about twenty-four hours after these footpads had been inoculated with antigen solution and sterile saline, respectively.

20

Similar results were obtained during the second phase of the study, in which the average difference was 42.33 micrometers, as evidenced by the following data:

TABLE 5

Mouse	Foot (left/right)	Foot Pad (untreated) (micrometers)	Foot Pad (final) (micrometers)	Foot Pad (difference) (micrometers)
1	Left (control)	1955.80	2032.00	76.20
	Right (test)	1981.20	2082.80	101.60
2	Left (control)	2006.60	2057.40	50.80
	Right (test)	2032.00	2108.20	76.20
3	Left (control)	1955.80	2006.60	50.80
	Right (test)	1930.40	2057.40	127.00
4	Left (control)	1955.80	2082.80	127.00
	Right (test)	1905.00	2032.00	127.00
5	Left (control)	2032.00	2082.80	50.80
	Right (test)	2057.40	2184.40	127.00
6	Left (control)	1955.80	1955.80	0.00
	Right (test)	2006.60	2057.40	50.80

- 5 As these results are comparable to (*i.e.*, not significantly greater than) those obtained with heat-sterilized solutions (*see* the results from EXAMPLES 3 and 4), it is apparent that heat sterilization of a solution that includes transfer factor does not significantly diminish or reduce the activity of the transfer factor.

10 EXAMPLE 6

This conclusion was verified by data from another mouse footpad assay, in which six BALB/c mice were inoculated, behind the neck, with 0.5 ml of a solution including 16% solids (w/v) of a spray-dried colostrum fraction that had been reconstituted in distilled, deionized water. About twenty-four hours later, the mice were anesthetized with isoflurane, then footpads on their hind feet measured and inoculated in the manner described above (*i.e.*, left footpad with sterile saline, right footpad with the antigen solution). After about another twenty-four hours, the footpads were again measured. The right footpads of these mice swelled, on average, about 42.33 micrometers more than the footpads on the left hind feet of these mice. This value is comparable to (*i.e.*, not significantly different from) the differences noted above with respect to the second, third, and fourth groups of mice in both the first and second phases of the study detailed in EXAMPLES 2 through 5 and 7, further

supporting the conclusion that heat sterilization of a solution that includes transfer factor, such as the solutions that were tested on the second and third groups of mice (EXAMPLES 3 and 4) does not have a significant adverse affect on the activity of the transfer factor.

5

EXAMPLE 7

The fact that the transfer factor with which the mice were inoculated was responsible for the increased secondary immune response is supported by the results from the fifth group, or positive control group, of mice during the second phase of the study, as set forth in the following table:

10

TABLE 6

Mouse	Foot (left/right)	Foot Pad (untreated) (micrometers)	Foot Pad (final) (micrometers)	Foot Pad (difference) (micrometers)
1	Left (control)	1981.20	2006.60	25.40
	Right (test)	2006.60	2082.80	76.20
2	Left (control)	1828.80	1854.20	25.40
	Right (test)	1879.60	2082.80	203.20
3	Left (control)	1905.00	1930.40	25.40
	Right (test)	1981.20	2082.80	101.60
4	Left (control)	2006.60	2057.40	50.80
	Right (test)	2032.00	2184.40	152.40
5	Left (control)	2032.00	2057.40	25.40
	Right (test)	2057.40	2184.40	127.00
6	Left (control)	2108.20	2108.20	0.00
	Right (test)	2082.80	2184.40	101.60

These results, which show on average, 101.60 micrometers more swelling in the footpads that were inoculated with antigen solution over those that were inoculated with sterile saline, are similar to the 124.88 micrometer difference seen in the mice of the positive control group during the first phase of the mouse footpad study. The greater swelling in the antigen solution-inoculated footpads of the mice of the positive control group is indicative of a greater secondary immune response than that induced artificially by administration of transfer factor, as the mice of the positive control group had a sufficient period of time (*i.e.*, two weeks) to generate their own transfer factor and, thus, to mount their own secondary immune response to the antigen.

15

20

Once an edible preparation of the present invention has been manufactured, it may be introduced into a clean or sterile container for subsequent transport and storage.

EXAMPLE 8

5 In another study, mouse footpad assays were conducted to determine the effectiveness of transfer factor in heat-treated samples of a liquid solution that included transfer factor that had been stored for one year. In total, four samples were prepared, two each having a pH of about 4 and two each having a pH of about 7. All of the samples had been flash sterilized at a temperature of about 120° C. for about two
10 seconds to about four seconds. The samples were subsequently stored for one year, with one each of the pH = 4 and pH = 7 samples having been stored at room temperature (which varied from about 18° C. to about 25° C.) and one each of the pH = 4 and pH = 7 samples having been refrigerated (at temperatures of about 4° C.). After one year, the samples were lyophilized. Prior to testing, the lyophilized samples
15 were reconstituted to desired concentrations, then administered in the manner described above.

 In a first sample, which included liquid having a pH of about 4 that was stored at room temperature, footpad swelling was, on average, 50.80 micrometers greater in footpads that had been injected with antigen versus footpads that had merely been
20 injected with saline. These results were repeated in second (liquid of a pH of about 7 that was stored at room temperature), third (liquid of a pH of about 4 that was refrigerated), and fourth (liquid of a pH of about 7 that was refrigerated) samples, in which hind footpads that had been injected with antigen were, on average, respectively swollen 59.27, 67.73, and 63.50 micrometers more than hind footpads that were merely
25 injected with saline.

 Additionally, positive and negative controls were prepared as discussed above. In the positive control, the average difference in swelling between antigen-injected footpads and saline-injected footpads was 114.30 micrometers. In the negative control, the average difference in swelling between antigen-injected footpads and
30 saline-injected footpads was only 38.10 micrometers.

 Taken together, these data indicate that the increased swelling was due to the presence of transfer factor in the mice in the areas (hind footpads) into which antigen was introduced. Additionally, these data indicate that the transfer factor lost little or

none of its effectiveness after heat-treatment and prolonged storage. The activity of transfer factor in refrigerated samples appears to have been slightly higher than the activity of transfer factor in the room temperature samples.

Further, it appears from the foregoing that the pH at which the transfer factor is
5 maintained (about 4 or about 7) has little or no effect on its long term viability.

Although the foregoing description contains many specifics, these should not be construed as limiting the scope of the present invention, but merely as providing illustrations of some of the presently preferred embodiments. Similarly, other
10 embodiments of the invention may be devised which do not depart from the spirit or scope of the present invention. Features from different embodiments may be employed in combination. The scope of the invention is, therefore, indicated and limited only by the appended claims and their legal equivalents, rather than by the foregoing description. All additions, deletions and modifications to the invention as disclosed herein which fall within the meaning and scope of the claims are to be embraced
15 thereby.

CLAIMS

What is claimed:

1. A nutritional supplement, comprising:
5 a fruit component including at least an extract of at least one
oligoproanthocyanidin-containing fruit; and
an immune component configured to elicit a secondary immune response in a subject.
2. The nutritional supplement of claim 1, wherein the at least one
10 oligoproanthocyanadin-containing fruit comprises açai.
3. The nutritional supplement of claim 1, wherein the fruit component
comprises at least an extract of one or more of elderberry, grape, and pomegranate.
- 15 4. The nutritional supplement of any of claims 1-3, in a liquid form.
5. The nutritional supplement of claim 4, wherein the liquid comprises fruit
juice.
- 20 6. The nutritional supplement of any of claims 1-3, in a solid form.
7. The nutritional supplement of claim 6, further comprising:
a chewable base.
- 25 8. The nutritional supplement of any of claims 1-3, wherein the immune
component comprises transfer factor.
9. The nutritional supplement of claim 8, wherein the transfer factor
comprises at least one of avian transfer factor and bovine transfer factor.
- 30 10. The nutritional supplement of any of claims 1-3, further comprising:
at least one preservative.

11. The nutritional supplement of claim 10, wherein the at least one preservative comprises at least one of lactoferrin, lysozyme and lactoperoxidase.

12. The nutritional supplement of any of claims 1-3, comprising a stored
5 state.

13. The nutritional supplement of claim 12, wherein the fruit component and the immune component are sterile in the stored state.

10 14. The nutritional supplement of claim 12, wherein the fruit component and the immune component are pasteurized in the stored state.

15 15. The nutritional supplement of claim 12, wherein the fruit component and the immune component are held at a temperature of about 4 °C. in the stored state.

16. A method for manufacturing a nutritional supplement, comprising:
forming a mixture including an immune component and a fruit component that includes
at least an extract of at least one oligoproanthocyanidin-containing fruit.

20 17. The method of claim 16, further comprising:
preventing microorganisms from growing in the mixture.

25 18. The method of claim 17, wherein preventing comprises sterilizing the mixture.

19. The method of claim 17, wherein preventing comprises pasteurizing the mixture.

30 20. The method of any of claims 17-19, wherein preventing comprises chilling the mixture.

21. The method of any of claims 17-19, wherein forming the mixture comprises forming a mixture further including at least one preservative.

22. The method of claim 21, wherein forming the mixture comprises forming a mixture including at least one of lysozyme and lactoperoxidase.

5 23. The method of any of claims 17-19, wherein forming the mixture comprises forming a mixture further including lactoferrin.

24. The method of any of claims 16-19, wherein forming the mixture comprises forming a mixture including at least one liquid component.

10

25. The method of claim 24, wherein forming the mixture comprises forming a mixture including a juice of the at least one oligoproanthocyanidin-containing fruit.

15 26. The method of claim 24, further comprising:
drying the mixture.

27. The method of claim 16, wherein forming the mixture comprises forming a mixture including only dry components.

20

28. The method of any of claims 16-19, wherein forming the mixture includes forming a mixture including an immune component comprising transfer factor and the fruit component.

25 29. An edible fluid, comprising:
a liquid or semisolid edible preparation including at least one proanthocyanidin; and
an immune component.

30 30. The edible fluid of claim 29, wherein the immune component comprises
transfer factor.

31. The edible fluid of claim 29, wherein the liquid or semisolid edible preparation includes a fruit or an extract of the fruit.

32. The edible fluid of claim 31, wherein the fruit or the extract of the fruit includes an oligoproanthocyanidin.

5 33. The edible fluid of claim 32, wherein the fruit or the extract of the fruit comprises açai or an extract of açai.

34. The edible fluid of any of claims 30-33, wherein the transfer factor comprises an avian transfer factor.

10

35. The edible fluid of any of claims 30-33, wherein the transfer factor comprises bovine transfer factor.

36. The edible fluid of claim 35, wherein the transfer factor further
15 comprises avian transfer factor.